SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors anticipate a major catalyst from the final survival events of its Phase 3 REGAL trial for GPS, while the stock faces significant volatility driven by a massive short squeeze. The community is intensely debating whether this momentum will trigger a potential buyout, with bulls pointing to revolutionary clinical data and shorts facing severe margin pressure due to extremely high borrow costs.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending due to volatile price action and intense debate surrounding the reopening of the Strait of Hormuz following a new U.S.-Iran memorandum of understanding. The community is heavily divided, with bears pointing to increased tanker traffic and Iranian sanctions relief as signs of a supply-driven price collapse, while bulls are actively discussing potential short squeezes and the impact of depleted global oil reserves.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is experiencing significant volatility as market participants debate the timing of potential regulatory clarity and the impact of institutional integration on price stability. The community remains deeply divided, with some investors accumulating through the downturn while others express frustration over extended periods of consolidation and ongoing selling pressure.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is capturing market attention after receiving FDA approval for Lumvoa to treat Thyroid Eye Disease, a milestone that transitions the company into a commercial-stage entity with a fully funded path to profitability. The community is actively debating the stock's valuation upside against its primary competitor, Amgen's Tepezza, while closely monitoring upcoming conference calls for details on pricing strategy and market launch metrics.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent Biosolutions is currently a focus for investors as the company executes a multi-year turnaround strategy under CEO Joe Papa, highlighting recent strategic manufacturing partnerships and expanded international approvals for its ACAM2000 vaccine. Community discussion is heavily divided, with some investors betting on a potential short squeeze fueled by significant short interest and contract-based upside, while skeptics remain focused on the company's debt profile and the volatility of its public health-dependent business model.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is experiencing significant volatility and a sharp sell-off following the release of Phase 3 maintenance trial data for its ulcerative colitis drug, obefazimod, which triggered concerns over reported malignancy cases. While the community is debating whether these safety signals are statistically significant or merely background noise, many are viewing the price drop as an overreaction and a potential buying opportunity for a buyout candidate with strong efficacy results.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Trulieve Cannabis Corp is trending as investors monitor the upcoming administrative hearing regarding the potential rescheduling of cannabis to Schedule III, a move widely anticipated to ease federal banking and regulatory burdens for the sector. Community sentiment remains focused on the company's fundamental performance and strategic expansion efforts as a major multi-state operator despite recent volatility.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

Grayscale Bitcoin Trust is trending amidst intense community debate over whether the asset is entering a prolonged "crypto winter" or remains a long-term hedge against fiat devaluation. Investors are closely monitoring massive capital outflows from spot ETFs and diverging analyst perspectives on whether recent price volatility signals an imminent market bottom or a deeper cyclical correction.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

ProShares Ultra Bloomberg Crude Oil (UCO) is trending as traders debate the potential impact of escalating tensions in the Strait of Hormuz against reports of shifting diplomatic efforts and rising production levels from major oil-producing nations. Community discussions are heavily focused on navigating the volatility created by these conflicting geopolitical signals, with many actively trading leveraged oil instruments based on shifting news cycles.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

The community is intensely focused on the Grayscale Bitcoin Mini Trust as market participants weigh conflicting signals regarding Bitcoin's near-term price floor, with many debating if recent volatility represents a classic bull trap or a setup for a significant short squeeze. Active discussions center on the interplay between technical support levels near $60,000, the impact of institutional accumulation, and broader macroeconomic factors affecting the crypto sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
